April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
Immune Homeostatic Mechanisms Suppress Experimental Autoimmune Uveitis
Author Affiliations & Notes
  • Andrew W. Taylor
    Ophthalmology, Boston University School of Medicine, Boston, Massachusetts
  • Darren J. Lee
    Ophthalmology, Boston University School of Medicine, Boston, Massachusetts
  • Norikuni Kawanaka
    Clinical Research and Internal Medicine, Zentsuji National Hospital, Kagawa, Japan
  • Michail Sitkovsky
    Biology, Northeastern University, Boston, Massachusetts
  • Akio Ohta
    Biology, Northeastern University, Boston, Massachusetts
  • Footnotes
    Commercial Relationships  Andrew W. Taylor, None; Darren J. Lee, None; Norikuni Kawanaka, None; Michail Sitkovsky, None; Akio Ohta, None
  • Footnotes
    Support  NIH Grant EY010752, and the Massachusetts Lions Eye Research Foundation
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 2262. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Andrew W. Taylor, Darren J. Lee, Norikuni Kawanaka, Michail Sitkovsky, Akio Ohta; Immune Homeostatic Mechanisms Suppress Experimental Autoimmune Uveitis. Invest. Ophthalmol. Vis. Sci. 2011;52(14):2262.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : The rodent models of uveitis demonstrate that left untreated the ocular microenvironment reimposes immunosuppression and resolves uveitis. This may be possible because the ocular microenvironment promotes mechanisms of immune homeostasis. Two possible homeostatic pathways are the hypoxia-adenosinergic (H-A) pathway mediated by adenosine through A2A receptors (A2Ar) on T cells, and the melanocortin pathway mediated by α-MSH. The two pathways are linked through the activation of HIF-1α. Therefore, we assessed whether it is possible to engage the H-A pathway during uveitis, and assess if any α-MSH activity requires HIF-1α activation.

Methods: : C57BL/6 mice were immunized with IRBP to induce experimental autoimmune uveitis (EAU). The mice were injected i.p. three times either at the start or during the chronic phase of uveitis with A2Ar agonist GCS21680 (GCS). Fundus exams were conducted, and the retinitis was scored. Spleen cells were collected to assay IRBP-specific T cell production of IFN-γ, IL-17, and TGF-β. The apoptotic program was activated in macrophages to assess their rescue by α-MSH with the addition of HIF1α-inhibitor, and incubated for 24 hours. The cells were assayed for viability, and by TUNEL staining.

Results: : The clinical scores of EAU were significantly suppressed regardless of when GCS was injected and remained suppressed. The recovery from EAU was no different in the mice GCS injected at the onset of EAU compared to a PBS injected control, but was significantly accelerated in the mice GCS injected at the start of the chronic phase of EAU. Along with the accelerated recovery was an early induction of IRBP-specific Treg cells in the mouse spleens. In addition, macrophages could not be rescued from apoptosis by α-MSH in the presence of HIF1α-inhibitor.

Conclusions: : The H-A pathway can be engaged during uveitis to suppress the severity, and to accelerate the resolution of autoimmune uveitis. In addition, α-MSH mediated ocular immunomodulation may also function through the H-A pathway. These results imply that the mechanisms of ocular immune privilege include normal immune homeostatic pathways.

Keywords: immunomodulation/immunoregulation • immune tolerance/privilege • autoimmune disease 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.